GPB Passport icon GPB Passport icon Passport
GPB donate icon GPB donate icon Donate
Sign Up For Our Newsletter

News Articles: Wegovy

Injectable weight-loss drugs are becoming a multi-billion dollar market, but they are not covered by Medicare. The drugmakers are trying to change that.

Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.

|
By:
  • Rachana Pradhan
ShantaQuilette Develle Carter-Williams, 44, was prescribed Ozempic after a stroke put her life in danger. The drug worked wonders — until she couldn't get it.

'You forget to eat': How Ozempic went from diabetes medicine to blockbuster diet drug

The Novo Nordisk diabetes medication was found to cause significant weight loss in users and has since become a blockbuster drug and very big business.

|
By:
  • Stacey Vanek Smith
Wegovy has been called "a major breakthrough" given how well it works to reduce body weight. But the injection drug is extremely expensive and when people can't afford to stay on it, they experience rebound weight gain that's hard to stop.

Wegovy works. But here's what happens if you can't afford to keep taking the drug

The new weight-loss drugs can be life-changing for people facing health conditions worsened by obesity, but price and spotty insurance coverage may keep them out of reach.

|
By:
  • Allison Aubrey